Enhanced Control of Mercury and other HAP by Innovative Modifications to Wet FGD Processes

The overall objective of this project was to learn more about controlling emissions of hazardous air pollutants (HAPs) from coal-fired power plants that are equipped with wet flue gas desulfurization (FGD) systems. The project was included by FETC as a Phase I project in its Mega-PRDA program. Phase I of this project focused on three research areas. These areas in order of priority were: (1) Catalytic oxidation of vapor-phase elemental mercury; (2) Enhanced particulate-phase HAPs removal by electrostatic charging of liquid droplets; and (3) Enhanced mercury removal by addition of additives to FGD process liquor. Mercury can exist in two forms in utility flue gas--as elemental mercury and as oxidized mercury (predominant form believed to be HgCl{sub 2}). Previous test results have shown that wet scrubbers effectively remove the oxidized mercury from the gas but are ineffective in removing elemental mercury. Recent improvements in mercury speciation techniques confirm this finding. Catalytic oxidation of vapor-phase elemental mercury is of interest in cases where a wet scrubber exists or is planned for SO{sub 2} control. If a low-cost process could be developed to oxidize all of the elemental mercury in the flue gas, then the maximum achievable mercury removal across the existing or planned wet scrubber would increase. Other approaches for improving control of HAPs included a method for improving particulate removal across the FGD process and the use of additives to increase mercury solubility. This paper discusses results related only to catalytic oxidation of elemental mercury

Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer

Repetitive, low-dose (metronomic; METRO) drug administration of some anticancer agents can overcome drug resistance and increase drug efficacy in many cancers, but the mechanisms are not understood fully. Previously, we showed that METRO dosing of topotecan (TOPO) is more effective than conventional (CONV) dosing in aggressive human prostate cancer (PCa) cell lines and in mouse tumor xenograft models. To gain mechanistic insights into METRO-TOPO activity, in this study we determined the effect of METRO- and CONV-TOPO treatment in a panel of human PCa cell lines representing castration-sensitive/resistant, androgen receptor (+/−), and those of different ethnicity on cell growth and gene expression. Differentially expressed genes (DEGs) were identified for METRO-TOPO therapy and compared to a PCa patient cohort and The Cancer Genome Atlas (TCGA) database. The top five DEGs were SERPINB5, CDKN1A, TNF, FOS, and ANGPT1. Ingenuity Pathway Analysis predicted several upstream regulators and identified top molecular networks associated with METRO dosing, including tumor suppression, anti-proliferation, angiogenesis, invasion, metastasis, and inflammation. Further, the top DEGs were associated with increase survival of PCa patients (TCGA database), as well as ethnic differences in gene expression patterns in patients and cell lines representing African Americans (AA) and European Americans (EA). Thus, we have identified candidate pharmacogenomic biomarkers and novel pathways associated with METRO-TOPO therapy that will serve as a foundation for further investigation and validation of METRO-TOPO as a novel treatment option for prostate cancers.</jats:p

Table4_Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer.docx

Repetitive, low-dose (metronomic; METRO) drug administration of some anticancer agents can overcome drug resistance and increase drug efficacy in many cancers, but the mechanisms are not understood fully. Previously, we showed that METRO dosing of topotecan (TOPO) is more effective than conventional (CONV) dosing in aggressive human prostate cancer (PCa) cell lines and in mouse tumor xenograft models. To gain mechanistic insights into METRO-TOPO activity, in this study we determined the effect of METRO- and CONV-TOPO treatment in a panel of human PCa cell lines representing castration-sensitive/resistant, androgen receptor (+/−), and those of different ethnicity on cell growth and gene expression. Differentially expressed genes (DEGs) were identified for METRO-TOPO therapy and compared to a PCa patient cohort and The Cancer Genome Atlas (TCGA) database. The top five DEGs were SERPINB5, CDKN1A, TNF, FOS, and ANGPT1. Ingenuity Pathway Analysis predicted several upstream regulators and identified top molecular networks associated with METRO dosing, including tumor suppression, anti-proliferation, angiogenesis, invasion, metastasis, and inflammation. Further, the top DEGs were associated with increase survival of PCa patients (TCGA database), as well as ethnic differences in gene expression patterns in patients and cell lines representing African Americans (AA) and European Americans (EA). Thus, we have identified candidate pharmacogenomic biomarkers and novel pathways associated with METRO-TOPO therapy that will serve as a foundation for further investigation and validation of METRO-TOPO as a novel treatment option for prostate cancers.</p